Pasireotide ditrifluoroacetate (C09-1165-426)

Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibiAppearance:SolidIC50& Target:pKi: 8.2 (sst1), 9.0 (sst2), 9.1 (sst3), <7.0 (sst4), 9.9 (sst5)In Vitro:Pasireotide ditrifluoroacetate exhibits unique high-affinity binding to human somatostatin receptors (subtypes sst1/2/3/4/5, pK i =8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate effectively inhibits the growth hormone releasing hIn Vivo:Pasireotide ditrifluoroacetate (160mg/kg/mouth; s.c. for 4 months) significantly decreases the serum insulin, increases serum glucose, reduces the tumor size and increases apoptosis in Pdx1-Cre. Pasireotide ditrifluoroacetate (2-50 μg/kg; s.c. twiceBiological Activity:Pasireotide (SOM230) ditrifluoroacetate, a long-acting cyclohexapeptide somatostatin analogue, can improve agonist activity at somatostatin receptors (subtypes sst1/2/3/4/5 , pK i =8.2/9.0/9.1/<7.0/9.9, respectively). Pasireotide ditrifluoroacetate exhibi. Specifications and Purity: 99%. Molecular Formula: C62H68F6N10O13. Molecular Weight: 1275.25.